Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 229 full-time employees. The firm develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. The company is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Follow-Up Questions
GERN hissesinin fiyat performansı nasıl?
GERN 'in mevcut fiyatı $1.33 'dir, son işlem günde 0.98% increased etti.
Geron Corp için ana iş temaları veya sektörler nelerdir?
Geron Corp Biotechnology endüstrisine ait ve sektör Health Care 'dir
Geron Corp 'in piyasa değerlemesi nedir?
Geron Corp 'in mevcut piyasa değerlemesi $850.4M 'dir
Geron Corp al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 10 analist Geron Corp için analist derecelendirmeleri gerçekleştirdi, bunlar 5 güçlü al, 6 al, 3 tut, 1 sat ve 5 güçlü sat içermektedir
